ID

26242

Descripción

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Screening/Enrollment

Palabras clave

Versiones (6)
  1. 25/8/17 25/8/17 -
  2. 25/8/17 25/8/17 -
  3. 25/8/17 25/8/17 -
  4. 13/10/17 13/10/17 -
  5. 23/10/17 23/10/17 -
  6. 12/12/17 12/12/17 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

13 de octubre de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Screening/Enrollment GSK study Chronic Coronary Heart Disease NCT00799903

Inglés

Screening/Enrollment GSK study Chronic CHD NCT00799903

1 formularios  
Screening
Descripción

Screening

1. Subject initials
Descripción

This item is hidden to all users and will be autopopulated by the system as "---"

Tipo de datos

text

2. Date of birth
Descripción

Will be automatically mapped to demography form

Tipo de datos

date

3. eGFR value used for screening
Descripción

eGFR

Tipo de datos

integer

4. Was this subject a screen failure?
Descripción

If Yes, check all that apply. If you are not collecting data on screen failures then the Screen Failure question cannot be removed from the SCREEN form, although the list of reasons can be edited. Subject Number is optional. If not needed, remove control and from the group control.

Tipo de datos

boolean

Reason for screen failure
Descripción

Reason for screen failure

[F01] Did not meet inclusion/exclusion criteria
Descripción

Inclusion exclusion criteria

Tipo de datos

boolean

[F10] Subject withdrew consent prior to randomisation
Descripción

Withdrawal of consent

Tipo de datos

boolean

[F06] Study closed/terminated prior to randomisation
Descripción

Study closed/terminated

Tipo de datos

boolean

[F07] Lost to follow up prior to randomisation
Descripción

Lost to follow up

Tipo de datos

boolean

If subject did not meet inclusion/exclusion criteria, specify:
Descripción

If subject did not meet inclusion/exclusion criteria, specify:

[I02] Inclusion Criteria 2: Male or female at least 18 years old at screening and females postmenopausal or using highly effective method to avoid pregnancy
Descripción

Inclusion Criteria sex pregnancy

Tipo de datos

boolean

[I03] Inclusion Criteria 3: Current treatment with statin therapy unless contraindicated
Descripción

Inclusion Criteria statin therapy

Tipo de datos

boolean

[I04] Inclusion Criteria 4: Chronic CHD documented
Descripción

Inclusion Criteria Chronic CHD

Tipo de datos

boolean

[I05] Inclusion Criteria 5: At least one additional predictor of CV risk
Descripción

Inclusion Criteria additional predictors of CV risk

Tipo de datos

boolean

[E01] Exclusion Criteria 1: Planned coronary revascularization (PCI or CABG) or any other major surgical procedure
Descripción

Exclusion Criteria Planned coronary PCI or CABG

Tipo de datos

boolean

[E02] Exclusion Criteria 2: Current liver disease, known hepatic or biliary abnormalities evidence of abnormal liver function tests
Descripción

Exclusion Criteria abnormal liver function

Tipo de datos

boolean

[E03] Exclusion Criteria 3: Severe renal impairment or history of nephrectomy or kidney transplant
Descripción

Exclusion Criteria renal impairment

Tipo de datos

boolean

[E04] Exclusion Criteria 4: Current severe heart failure
Descripción

Exclusion Criteria heart failure

Tipo de datos

boolean

[E05] Exclusion Criteria 5: Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy
Descripción

Exclusion Criteria hypertension

Tipo de datos

boolean

[E06] Exclusion Criteria 6: Any life-threatening condition with life expectancy less than 2 years
Descripción

Exclusion Criteria life expectancy less than 2 years

Tipo de datos

boolean

[E07] Exclusion Criteria 7: Severe asthma that is poorly controlled on pharmacotherapy
Descripción

Exclusion Criteria asthma

Tipo de datos

boolean

[E08] Exclusion Criteria 8: Positive pregnancy test or is known to be pregnant or lactating
Descripción

Exclusion Criteria pregnancy

Tipo de datos

boolean

[E09] Exclusion Criteria 9: History of anaphylaxis, anaphylactoid reactions severe allergic responses
Descripción

Exclusion Criteria allergy

Tipo de datos

boolean

[E10] Exclusion Criteria 10: Alcohol or drug abuse within the past 6 months, or current mental condition which may affect study compliance
Descripción

Exclusion Criteria Alcohol or drug abuse

Tipo de datos

boolean

[E11] Exclusion Criteria 11: Current or planned chronic administration of strong oral or injectable CYP3A4 inhibitors
Descripción

Exclusion Criteria CYP3A4 inhibitors

Tipo de datos

boolean

[E12] Exclusion Criteria 12: Subjects with both parents of Japanese, Chinese, or Korean ancestry with Lp-PLA2 activity less or eq 20 nmol/min/mL
Descripción

Exclusion Criteria Lp-PLA2 activity

Tipo de datos

boolean

[E13] Exclusion Criteria 13: Previous exposure to darapladib (SB-480848)
Descripción

Exclusion Criteria exposure to darapladib

Tipo de datos

boolean

[E14] Exclusion Criteria 14: Use of another investigational product within 30 days or 5 half-lives preceding the first dose of darapladib or matching placebo
Descripción

Exclusion Criteria Use of other IP

Tipo de datos

boolean

[E15] Exclusion Criteria 15: Currently in a study of an investigational device
Descripción

Exclusion Criteria study of investigational device

Tipo de datos

boolean

[E16] Exclusion Criteria 16: Any other reason the investigator deems the subject to be unsuitable for the study
Descripción

Exclusion Criteria other

Tipo de datos

boolean

[E16] Exclusion Criteria 16, specify:
Descripción

Exclusion Criteria other specification

Tipo de datos

text

Volver a la parte superior de la página

Similar models

Screening/Enrollment GSK study Chronic CHD NCT00799903

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Screening
Subject initials
Item
1. Subject initials
text
Date of birth
Item
2. Date of birth
date
eGFR
Item
3. eGFR value used for screening
integer
screen failure
Item
4. Was this subject a screen failure?
boolean
Item Group
Reason for screen failure
Inclusion exclusion criteria
Item
[F01] Did not meet inclusion/exclusion criteria
boolean
Withdrawal of consent
Item
[F10] Subject withdrew consent prior to randomisation
boolean
Study closed/terminated
Item
[F06] Study closed/terminated prior to randomisation
boolean
Lost to follow up
Item
[F07] Lost to follow up prior to randomisation
boolean
Item Group
If subject did not meet inclusion/exclusion criteria, specify:
Inclusion Criteria sex pregnancy
Item
[I02] Inclusion Criteria 2: Male or female at least 18 years old at screening and females postmenopausal or using highly effective method to avoid pregnancy
boolean
Inclusion Criteria statin therapy
Item
[I03] Inclusion Criteria 3: Current treatment with statin therapy unless contraindicated
boolean
Inclusion Criteria Chronic CHD
Item
[I04] Inclusion Criteria 4: Chronic CHD documented
boolean
Inclusion Criteria additional predictors of CV risk
Item
[I05] Inclusion Criteria 5: At least one additional predictor of CV risk
boolean
Exclusion Criteria Planned coronary PCI or CABG
Item
[E01] Exclusion Criteria 1: Planned coronary revascularization (PCI or CABG) or any other major surgical procedure
boolean
Exclusion Criteria abnormal liver function
Item
[E02] Exclusion Criteria 2: Current liver disease, known hepatic or biliary abnormalities evidence of abnormal liver function tests
boolean
Exclusion Criteria renal impairment
Item
[E03] Exclusion Criteria 3: Severe renal impairment or history of nephrectomy or kidney transplant
boolean
Exclusion Criteria heart failure
Item
[E04] Exclusion Criteria 4: Current severe heart failure
boolean
Exclusion Criteria hypertension
Item
[E05] Exclusion Criteria 5: Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy
boolean
Exclusion Criteria life expectancy less than 2 years
Item
[E06] Exclusion Criteria 6: Any life-threatening condition with life expectancy less than 2 years
boolean
Exclusion Criteria asthma
Item
[E07] Exclusion Criteria 7: Severe asthma that is poorly controlled on pharmacotherapy
boolean
Exclusion Criteria pregnancy
Item
[E08] Exclusion Criteria 8: Positive pregnancy test or is known to be pregnant or lactating
boolean
Exclusion Criteria allergy
Item
[E09] Exclusion Criteria 9: History of anaphylaxis, anaphylactoid reactions severe allergic responses
boolean
Exclusion Criteria Alcohol or drug abuse
Item
[E10] Exclusion Criteria 10: Alcohol or drug abuse within the past 6 months, or current mental condition which may affect study compliance
boolean
Exclusion Criteria CYP3A4 inhibitors
Item
[E11] Exclusion Criteria 11: Current or planned chronic administration of strong oral or injectable CYP3A4 inhibitors
boolean
Exclusion Criteria Lp-PLA2 activity
Item
[E12] Exclusion Criteria 12: Subjects with both parents of Japanese, Chinese, or Korean ancestry with Lp-PLA2 activity less or eq 20 nmol/min/mL
boolean
Exclusion Criteria exposure to darapladib
Item
[E13] Exclusion Criteria 13: Previous exposure to darapladib (SB-480848)
boolean
Exclusion Criteria Use of other IP
Item
[E14] Exclusion Criteria 14: Use of another investigational product within 30 days or 5 half-lives preceding the first dose of darapladib or matching placebo
boolean
Exclusion Criteria study of investigational device
Item
[E15] Exclusion Criteria 15: Currently in a study of an investigational device
boolean
Exclusion Criteria other
Item
[E16] Exclusion Criteria 16: Any other reason the investigator deems the subject to be unsuitable for the study
boolean
Exclusion Criteria other specification
Item
[E16] Exclusion Criteria 16, specify:
text
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial